ProPhase Labs Q2 2026: $3.05M Loss, $20K Cash, Going Concern Doubt Persists
PRPH is trading near its 52-week low of $0.028 (3.9% above the low) on elevated volume (4.4× avg).
Summary
ProPhase Labs' Q2 2026 report shows a $3.05M loss, only $20K in cash, and a going concern warning. Subsequent convertible debt deals add more dilution risk.
Key Events · Earnings and Guidance · PRPH
-
Q2 Net Loss of $3.05M
Net loss from continuing operations was $3.05 million for Q2 2026, compared to $4.47 million in Q2 2025. Six-month loss was $8.23 million versus $0.51 million in H1 2025.
-
Cash Drops to $20,000
Cash and cash equivalents fell to $20,000 as of June 30, 2026, from $90,000 at year-end 2025. Working capital deficit widened to $55.3 million.
-
Going Concern Doubt Reiterated
Management states substantial doubt about the company's ability to continue as a going concern within one year, and its plans do not alleviate that doubt.
-
Ineffective Disclosure Controls
Disclosure controls and procedures were concluded ineffective as of June 30, 2026.
Analysis · PRPH · Life Sciences
A $3.05 million net loss in Q2 2026 left ProPhase Labs with just $20,000 in cash and a $55.3 million working capital deficit. Management reiterated substantial doubt about the company's ability to continue as a going concern, stating its plans do not alleviate that doubt. The filing also discloses ineffective disclosure controls and a series of post-quarter convertible debt deals with deep discounts that will further dilute shareholders. This is a critical update on a company already in severe distress.
At the time of this filing, PRPH was trading at $0.03 on OTC in the Life Sciences sector, with a market capitalization of approximately $276.3K. The 52-week trading range was $0.03 to $66.59. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.